Australia markets open in 4 hours 19 minutes

Spectral Medical Inc. (SD4.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3260-0.0120 (-3.55%)
As of 08:02AM CEST. Market open.
Full screen
Previous close0.3380
Open0.3260
Bid0.3240 x 1000000
Ask0.3500 x 1000000
Day's range0.3260 - 0.3260
52-week range0.1980 - 0.4520
Volume302
Avg. volume131
Market cap91.082M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Spectral Medical Inc. Announces Closing of Additional US$1 Million Convertible Notes

    Large shareholder exercises anti-dilution pre-emptive rightsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral") is pleased to announce the closing of an additional non-brokered offering of US$1 milli

  • GlobeNewswire

    Spectral Medical Inc. Announces Change to Auditor

    TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that MNP LLP (“MNP”) have today been appointed as the auditors of the Company following the decision by PricewaterhouseCoopers LLP (“PwC”) to resign as the auditor of Spectral (the “Effective Date”). The resignation of PwC as the auditor of Spectral and the appointment of MNP as audit

  • GlobeNewswire

    Spectral Medical Provides June Tigris Trial Update

    116 patients enrolledJune represents a new record breaking month for patient enrollment TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and sept